Wilfried E E Eberhardt
Overview
Explore the profile of Wilfried E E Eberhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
8537
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, et al.
J Thorac Oncol
. 2025 Feb;
PMID: 39927917
No abstract available.
2.
Tsao M, Rosenthal A, Nicholson A, Detterbeck F, Eberhardt W, Lievens Y, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39864546
Introduction: Pulmonary high-grade neuroendocrine carcinoma (NEC) includes SCLC and large cell NEC (LCNEC). The seventh and eighth editions of the TNM classification for lung cancer confirmed the applicability of this...
3.
Mavroeidi I, Romanowicz A, Haake T, Wienker J, Metzenmacher M, Darwiche K, et al.
Theranostics
. 2024 Sep;
14(14):5400-5412.
PMID: 39310095
Positron Emission Tomography (PET) using the somatostatin receptor 2 (SSTR2)-antagonist satoreotide trizoxetan (Ga-SSO120) is a novel, promising imaging modality for small-cell lung cancer (SCLC), which holds potential for theranostic applications....
4.
Kessler L, Schwaning F, Metzenmacher M, Pabst K, Siveke J, Trajkovic-Arsic M, et al.
J Nucl Med
. 2024 Jul;
65(8):1188-1193.
PMID: 38960716
The fibroblast activation protein (FAP) is highly expressed in tumor and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic target. Previous data on PET imaging with...
5.
Richlitzki C, Wiesweg M, Metzenmacher M, Guberina N, Pottgen C, Hautzel H, et al.
Sci Rep
. 2024 Jun;
14(1):13765.
PMID: 38877146
To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients...
6.
Eberhardt W, Sebastian M
J Thorac Oncol
. 2024 Jun;
19(6):849-851.
PMID: 38849162
No abstract available.
7.
Griesinger F, Sebastian M, Brueckl W, Hummel H, Jaeschke B, Kern J, et al.
JTO Clin Res Rep
. 2024 Apr;
5(4):100626.
PMID: 38586301
Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess...
8.
Guberina M, Pottgen C, Guberina N, Hoffmann C, Wiesweg M, Richlitzki C, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539510
In patients with oligometastatic NSCLC, a cT3-cT4 primary tumor or an cN2/cN3 lymph node status was reported to be associated with unfavorable outcome. The aim of this study was to...
9.
Sebastian M, Eberhardt W, von der Heyde E, Dorfel S, Wiegand J, Schiefer C, et al.
Int J Cancer
. 2024 Feb;
154(11):1967-1978.
PMID: 38329180
Patients with lung cancer under treatment have been associated with a high risk of COVID-19 infection and potentially worse outcome, but real-world data on patient-reported outcomes (PROs) are rare. We...
10.
Fong K, Rosenthal A, Giroux D, Nishimura K, Erasmus J, Lievens Y, et al.
J Thorac Oncol
. 2024 Feb;
19(5):786-802.
PMID: 38320664
Introduction: This study analyzed all metastatic categories of the current TNM classification of NSCLC to propose modifications of the M component in the next edition (ninth) of the classification. Methods:...